Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 10/22/2018

|Includes: Dova Pharmaceuticals (DOVA), SESN, TXMD
Summary

This week's Marketplace postings include interviews with experts discussing assets from: DOVA, SESN, TXMD.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: A look at Dova's avatrombopag (DOPTELET) with a gastroenterologist in the community setting

Ticker: DOVA

Who's the Expert?

  • Gastroenterologist in private practice (Brooklyn NY) who is a member of the American College of Gastroenterology and has prescribed DOPTELET.
  • Currently sees 200-300 patients/year with thrombocytopenia and about 1/2 will go on to have a procedure, most have plt though over 50k.
  • Has published in peer review journals and presented at national Gastroenterology society meetings. In 2006 he received the Young Investigators Award from Given Imaging, for his work on the use of Capsule Endoscopy in the diagnosis of Inflammatory Bowel Disease.

Interview Goal: To discuss the market potential of avatrombopag (DOPTELET), an orally administered TPO receptor in development by Dova Pharma with a prescriber in the community setting.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: Digging into the interim Phase 3 VISTA trial data for Sesen Bio's Non-Muscle Invasive Bladder Cancer Treatment, Vicinium - Part 2

Ticker: SESN

Who's the Expert?

  • Urologic Oncologist with over 21 years of experience, Attending Physician in the Department of Urology at Mount Sinai Beth Israel Medical Center and Professor of Urology at Icahn School of Medicine at Mount Sinai.
  • Currently manages 1000 patients with NMIBC.
  • Has authored over 150 papers and participated in many clinical trials for new drugs for urologic disorders.

Interview Goal:

To continue the conversation on the newly released interim Phase 3 VISTA trial data at 3 Months, of 133 patients who have been previously treated with BCG, and compare its efficacy and safety to existing therapies.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: Exploring TherapeuticsMD's approved Imvexxy in treating Genitourinary Syndrome of Menopause with a prescribing physician

Ticker: TXMD

Who's the Expert?

  • Professor, Department of Obstetrics and Gynecology & co-director of the Women’s Wellness Division of Gynecology at NYU who specializes in menopause and ERT with over 20 years of experience.
  • Currently treats 30 patients per month with VVA/GSM.
  • Significant research activity; conducted a comprehensive ten year prospective double blind placebo controlled study of estrogen replacement therapy and the relationship to carcinoma, cardiovascular disease, and osteoporosis in a sample of hospitalized women.

Interview Goal:

To discuss recently approved Imvexxy (formerly Yuvexxy, TX-004HR) vaginal estradiol with a prescribing physician.

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.